Abstract
Introduction
Several overdoses of the antiepileptic drug perampanel have been reported in adults, but very few have been reported in children. We report the case of an observed exploratory ingestion of perampanel in a 2-year-old child that resulted in ataxia and prolonged coma.
Case Report
A previously healthy 2-year-old female patient presented to the emergency department (ED) 30 minutes after the witnessed ingestion of 30 mg of perampanel (2 mg/kg). Within minutes of ingestion, she displayed ataxia and inability to walk. Upon ED presentation, she had normal vital signs but was minimally responsive with physical stimulation. Naloxone was given without response. She was intubated because of profound central nervous system depression and transferred to a pediatric tertiary care facility. She remained intubated with no pharmacological sedation. Physical exam showed a horizontal nystagmus. Detailed neurologic examination of ataxia and coordination was not possible, and she did not demonstrate hyperreflexia, clonus, or rigidity. Her mental status gradually improved, and she was extubated approximately 72 hours after exposure. After extubation, the patient still exhibited truncal ataxia and did not return to baseline until 96 hours post ingestion. Serum drawn approximately 16 hours after exposure showed 870 ng/mL perampanel (ref < 20 ng/mL). She remained hemodynamically stable throughout her hospital course, despite protracted depressed mental status.
Discussion
Given the severity of our patient’s presentation, pediatric patients showing symptoms of perampanel overdose should be triaged to the ED for evaluation in anticipation of a prolonged clinical course with decreased consciousness and hypoventilation.
Similar content being viewed by others
References
Inc E. FYCOMPA (TM) oral tablets. Product information. In: Inc E, editor. Woodcliff Lake; 2012.
Eisai announces FDA approval of FYCOMPA® in pediatric patients as young as 4 years old for the treatment of partial-onset seizures [press release]. Woodcliff Lake: Eisai2018.
LaPenna P, Tormoehlen LM. The pharmacology and toxicology of third-generation anticonvulsant drugs. J Med Toxicol. 2017;13(4):329–42.
Greenwood J, Valdes J. Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016;41(11):683–98.
Youn SE, Kim SH, Ko A, Lee SH, Lee YM, Kang HC, et al. Adverse events during perampanel adjunctive therapy in intractable epilepsy. J Clin Neurol. 2018;14(3):296–302.
Wu CC, McShane M, Huttlin EA, Novoa KC. Severe aggression after perampanel overdose: case report. Psychosomatics. 2019;60(3):321–4.
Qozi M, Cantrell FL. Pediatric perampanel poisoning. Am J Emerg Med. 2020;38(7):1545.e1-.e2.
Kim S, Kim TE, Kim D, Kim DW. Prolonged stupor in perampanel overdose and pharmacokinetic considerations. J Epilepsy Res. 2018;8(2):87–9.
Li K, Lasoff DR, Smollin CG, Ly BT. Perampanel overdose causing a prolonged coma. Clin Toxicol (Phila). 2018;56(7):677–8.
Parsons G, Bailey J, Bailey F, Brzezicki M. Prolonged unconsciousness in perampanel overdose. BMJ Case Rep. 2019;12(11):e232517.
Wachiropathum P, Nabangchang C, Likasitthananon N, Suwanpakdee P. Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand. Epilepsy Behav. 2021;118:107964.
Mir A, Almudhry M, Al-Ghamdi F, Bashir S. Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases. Epileptic Disord. 2021;23(2):385–91.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Consent for publication of this case was obtained and provided to the journal in accordance with JMT policy.
Conflicts of Interest
None.
Additional information
Supervising Editor: Andis Graudins, MB BS, PhD
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dean, D., Passalacqua, K.D. & Dolcourt, B. Truncal Ataxia and Prolonged Coma in an Exploratory Pediatric Perampanel Ingestion. J. Med. Toxicol. 17, 309–311 (2021). https://doi.org/10.1007/s13181-021-00847-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-021-00847-2